NT-101 / NexThera - LARVOL DELTA

The Purpose of This Study is to Evaluate Efficacy and Safety of NT-101 Eye Drops in Patients With Wet Age-Related Macular Degeneration (AMD) (clinicaltrials.gov) - P2 | N=66 | Recruiting | Sponsor: NexThera Co., Ltd.

New P2 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

NT-101 Topical Ophthalmic Solution in Patients With Wet AMD (clinicaltrials.gov) - P1/2 | N=20 | Completed | Sponsor: NexThera Co., Ltd. | Active, not recruiting ➔ Completed | N=30 ➔ 20

Enrollment change • Trial completion • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Therapeutic efficacy and mechanistic insights of NT-101 eye drop in wet age-related macular degeneration (ARVO 2026) - "The positive control group received intravitreal injections of Eylea®. These effects are mediated through LRP6 and 67LR, but are unrelated to VEGFR1 or VEGFR2. These findings suggest that NT-101 has strong potential as a therapeutic agent for the treatment of wet AMD."

Clinical • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration • FLT1 • TJP1

NT-101 Topical Ophthalmic Solution in Patients With Wet AMD (clinicaltrials.gov) - P1/2 | N=30 | Active, not recruiting | Sponsor: NexThera Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Mar 2026 | Trial primary completion date: Sep 2025 ➔ Dec 2025

Enrollment closed • Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

NexThera Completes First Patient Enrollment in U.S. Clinical Trial for ‘NT-101,’ an Eye Drop Treatment for Wet AMD (Businesswire) - "NexThera...announced on April 9th that it has completed the first patient enrollment for its Phase 1/2a clinical trial of NT-101, a novel eye drop treatment for wet AMD, at a clinical trial site in Pennsylvania on April 8th....This clinical trial will enroll a total of 30 wet AMD patients across four clinics in Maryland, Philadelphia, North Carolina, and Texas. The main goal is to assess the safety and tolerability of NT-101.... In the clinical trial, patients will receive either a low-dose or high-dose of NT-101 twice daily, in the morning and evening, for 4 weeks. This will be succeeded by a 4-week follow-up, making the total duration 8 weeks."

Trial status • Wet Age-related Macular Degeneration

NT-101 Topical Ophthalmic Solution in Patients with Wet AMD (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: NexThera Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration